I. Lipkovich

R. Baker, T. Hardy, I. Lipkovich, 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Using principal stratification in analysis of clinical trials

B. Ratitch, I. Lipkovich, Y. Qu, 2021, 2112.03352.

Evaluating the relationship between clinical and demographic characteristics of insulin-using people with diabetes and their health outcomes: a cluster analysis application

I. Lipkovich, A. Edwards, B. Benneyworth, 2021, BMC Health Services Research.

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy

J. Csernansky, R. Keefe, I. Lipkovich, 2009, BMC psychiatry.

Typology of patients with fibromyalgia: cluster analysis of duloxetine study patients

I. Lipkovich, E. Choy, P. Van Wambeke, 2014, BMC Musculoskeletal Disorders.

The Impact of Major Events on Ongoing Noninferiority Trials, With Application to COVID-19

B. Wiens, I. Lipkovich, 2020, Statistics in biopharmaceutical research.

Predictors of remission with placebo using an integrated study database from patients with major depressive disorder

L. Marangell, J. Nelson, I. Lipkovich, 2012, Current medical research and opinion.

When Doubly Robust Methods Meet Machine Learning for Estimating Treatment Effects from Real-World Data: A Comparative Study

Shu Yang, I. Lipkovich, Z. Kadziola, 2022, 2204.10969.

Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.

G. Molenberghs, B. Ratitch, N. Goel, 2019, Therapeutic innovation & regulatory science.

Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach

I. Lipkovich, J. Houston, J. Ahl, 2008, BMC psychiatry.

Using principal stratification in analysis of clinical trials

B. Ratitch, I. Lipkovich, Y. Qu, 2021, Statistics in medicine.

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

T. Hardy, I. Lipkovich, A. Heinloth, 2008, Therapeutics and clinical risk management.

Assessing the commonly used assumptions in estimating the principal causal effect in clinical trials

S. Ruberg, I. Lipkovich, Y. Qu, 2021, Statistics in Biopharmaceutical Research.

Bridging data across studies using frequentist and Bayesian estimation

Olga V. Marchenko, I. Lipkovich, Teng Zhang, 2017, Journal of biopharmaceutical statistics.

Weight-of-Evidence (WOE): Quantitative Estimation of Probability of Impairment for Individual and Multiple Lines of Evidence

Keying Ye, Eric P. Smith, Ilya Lipkovich, 2002 .

Bayesian Model Averaging and Variable Selection in Multivariate Ecological Models

I. Lipkovich, 2002 .

Evaluating the Impact of Environmental Stressors on Benthic Microinvertebrate Communities via Bayesian Model Averaging

Keying Ye, Eric P. Smith, Ilya Lipkovich, 2002 .

Statistical Data Mining of Clinical Data

Bohdana Ratitch, Ilya Lipkovich, Cristina Ivanescu, 2020 .

A two‐stage adaptive clinical trial design with data‐driven subgroup identification at interim analysis

I. Lipkovich, A. Dmitrienko, Yan Zhao, 2022, Pharmaceutical statistics.

Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis

Ilya Lipkovich, Tom Parke, I. Lipkovich, 2018, Pharmaceutical statistics.

Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice

G. Molenberghs, B. Ratitch, I. Lipkovich, 2020, Therapeutic Innovation & Regulatory Science.

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice

G. Molenberghs, B. Ratitch, N. Goel, 2020, Therapeutic Innovation & Regulatory Science.

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

E. Siemers, P. Aisen, R. Doody, 2015, Alzheimer's & dementia.

A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer’s Disease

E. Siemers, I. Lipkovich, H. Liu-Seifert, 2015, PloS one.

Points to consider for analyzing efficacy outcomes in long‐term extension clinical trials

Bohdana Ratitch, Ilya Lipkovich, Janelle Shannon Erickson, 2018, Pharmaceutical statistics.

In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005

A. Young, M. Tohen, T. Ketter, 2010, European Psychiatry.

Strategies for Identifying Predictive Biomarkers and Subgroups with Enhanced Treatment Effect in Clinical Trials Using SIDES

Ilya Lipkovich, Alex Dmitrienko, I. Lipkovich, 2014, Journal of biopharmaceutical statistics.

Covariate Adjustment for Logistic Regression Analysis of Binary Clinical Trial Data

G. Molenberghs, I. Lipkovich, P. Kulkarni, 2017 .

To adjust or not to adjust for baseline when analyzing repeated binary responses? The case of complete data when treatment comparison at study end is of interest

G. Molenberghs, I. Lipkovich, P. Kulkarni, 2015, Pharmaceutical statistics.

Analyzing Longitudinal Clinical Trial Data: A Practical Guide

I. Lipkovich, C. Mallinckrodt, 2016 .

Biomarker Evaluation and Subgroup Identification in a Pneumonia Development Program Using SIDES

Alex Dmitrienko, Ilya Lipkovich, I. Lipkovich, 2015 .

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

T. Hardy, I. Lipkovich, V. P. Hoffmann, 2008, BMC psychiatry.

Causal Inference and Estimands in Clinical Trials

Bohdana Ratitch, Ilya Lipkovich, Craig H. Mallinckrodt, 2020 .

Estimands, Estimators and Sensitivity Analysis in Clinical Trials

Geert Molenberghs, Bohdana Ratitch, Ilya Lipkovich, 2019 .

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.

G. Molenberghs, B. Ratitch, N. Goel, 2019, Therapeutic innovation & regulatory science.

The potential role of Marginal Structural Models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice

H. Möller, S. Dittmann, H. Grunze, 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

A 24-Week Randomized Study of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia or Schizoaffective Disorder in Patients with Prominent Depressive Symptoms

I. Lipkovich, H. Ascher-Svanum, B. Kinon, 2006, Journal of clinical psychopharmacology.

Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials.

I. Lipkovich, C. Beasley, V. P. Hoffmann, 2009, Psychopharmacology bulletin.

Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with Olanzapine

R. Perlis, I. Lipkovich, L. Citrome, 2006, Journal of clinical psychopharmacology.

Sensitivity to censored‐at‐random assumption in the analysis of time‐to‐event endpoints

Bohdana Ratitch, Ilya Lipkovich, Michael O’Kelly, 2016, Pharmaceutical statistics.

Weight Gain Risk Factor assessment checklist: overview and recommendation for use.

I. Lipkovich, T. Treuer, H. Lockman, 2011, Neuro endocrinology letters.

Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium.

C. Bowden, R. Baker, I. Lipkovich, 2007, Journal of psychiatric research.

Practical recommendations on double score matching for estimating causal effects

Shu Yang, I. Lipkovich, Z. Kadziola, 2021, Statistics in medicine.

Selection bias in the treatment effect for a principal stratum

Yongming Qu, Ilya Lipkovich, Stephen J. Ruberg, 2021, 2112.09541.

Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic

I. Lipkovich, Y. Qu, 2020, Therapeutic Innovation & Regulatory Science.

M E ] 2 2 N ov 2 02 1 1 Monotonicity assumptions in estimating the treatment effect for a principal stratum

Yongming Qu, Ilya Lipkovich, Stephen J. Ruberg, 2021 .

A Multiple-Imputation-Based Approach to Sensitivity Analyses and Effectiveness Assessments in Longitudinal Clinical Trials

Geert Molenberghs, Craig H Mallinckrodt, Ilya Lipkovich, 2014, Journal of biopharmaceutical statistics.

Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy.

J. Csernansky, J. Peuskens, I. Lipkovich, 2007, Journal of psychiatric research.

Combining Analysis Results from Multiply Imputed Categorical Data

I. Lipkovich, 2016 .

General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials

Alex Dmitrienko, Ilya Lipkovich, Arno Fritsch, 2016, Journal of biopharmaceutical statistics.

Antipsychotic medication and social cue recognition in chronic schizophrenia

D. Penn, P. Corrigan, I. Lipkovich, 2010, Psychiatry Research.

Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines

G. Molenberghs, B. Ratitch, N. Goel, 2020, Therapeutic Innovation & Regulatory Science.

A structured approach to choosing estimands and estimators in longitudinal clinical trials

C H Mallinckrodt, I Lipkovich, G Molenberghs, 2012, Pharmaceutical statistics.

The Role of Multiple Imputation in Noninferiority Trials for Binary Outcomes

B. Wiens, I. Lipkovich, 2018 .

Overview of modern approaches for identifying and evaluating heterogeneous treatment effects from clinical data

B. Ratitch, I. Lipkovich, A. Dmitrienko, 2023, Clinical trials.

Comments on "Optimizing early prediction for antipsychotic response in schizophrenia" by Chang et al.

I. Lipkovich, S. Kollack-Walker, Lei Chen, 2009, Journal of Clinical Psychopharmacology.

Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice.

G. Molenberghs, B. Ratitch, I. Lipkovich, 2019, Therapeutic innovation & regulatory science.

Biplot and Singular Value Decomposition Macros for Excel

Eric P. Smith, Ilya Lipkovich, E. Smith, 2002 .

Detecting pattern in biological stressor response relationships using model based cluster analysis

Keying Ye, Eric P. Smith, Ilya Lipkovich, 2008, Environmental and Ecological Statistics.

Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials.

L. Kappos, S. Lindborg, I. Lipkovich, 2019, Multiple sclerosis and related disorders.

Flexible-Dose Clinical Trials: Predictors and Outcomes of Antipsychotic Dose Adjustments

I. Lipkovich, D. Baron, J. Houston, 2005, Journal of clinical psychopharmacology.

Multiple imputation compared with restricted pseudo‐likelihood and generalized estimating equations for analysis of binary repeated measures in clinical studies

I. Lipkovich, Yuyan Duan, Saeeduddin Ahmed, 2005 .

Multiplicity considerations in subgroup analysis

Alex Dmitrienko, Ilya Lipkovich, I. Lipkovich, 2017, Statistics in medicine.

Evaluating bias control strategies in observational studies using frequentist model averaging

D. Madigan, I. Lipkovich, Z. Kadziola, 2022, Journal of biopharmaceutical statistics.

Integrating Randomized Placebo-Controlled Trial Data with External Controls: A Semiparametric Approach with Selective Borrowing

Shu Yang, I. Lipkovich, D. Faries, 2023, 2306.16642.

The challenges of evaluating dose response in flexible‐dose trials using marginal structural models

I. Lipkovich, C. Mallinckrodt, D. Faries, 2012, Pharmaceutical statistics.

Causal Inference and Estimands

Geert Molenberghs, Bohdana Ratitch, Ilya Lipkovich, 2019 .

Modern approaches for evaluating treatment effect heterogeneity from clinical trials and observational data.

B. Ratitch, I. Lipkovich, David Svensson, 2023, Statistics in medicine.

Evaluating dose response from flexible dose clinical trials

I. Lipkovich, D. Baron, C. Mallinckrodt, 2008, BMC psychiatry.

Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder

Ilya Lipkovich, I. Lipkovich, R. Obenchain, 2013, International journal of methods in psychiatric research.

Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis

I. Lipkovich, A. Heinloth, B. Kinon, 2009, BMC psychiatry.

A Multiple-Imputation-Based Approach to Sensitivity Analyses and Effectiveness Assessments in Longitudinal Clinical Trials

G. Molenberghs, I. Lipkovich, C. Mallinckrodt, 2014, Journal of biopharmaceutical statistics.

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy

J. Csernansky, R. Keefe, I. Lipkovich, 2009, BMC psychiatry.

A Time-response Measure to Assess Clinical Equivalence in Rheumatoid Arthritis: an Assessment Using Data From Clinical Trials of Biosimilars

B. Ratitch, S. Chow, I. Lipkovich, 2020, Statistics in Biopharmaceutical Research.

Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach

I. Lipkovich, J. Houston, J. Ahl, 2008, BMC psychiatry.

A Macro For Getting More Out Of Your ROC Curve

Ilya Lipkovich, Jennifer Lambert, I. Lipkovich, 2008 .

Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: A multidimensional data-driven approach

J. Csernansky, J. Peuskens, I. Lipkovich, 2009, Psychiatry Research.

A unified Bayesian framework for interval hypothesis testing in clinical trials

I. Lipkovich, Abhisek Chakraborty, Megan H. Murray, 2024, 2402.13890.